Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Lerodalcibep→

Lerodalcibep PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2250073-78-8
Molecular formula
C3427H5324N908O1045S40
Molecular weight
77247.08 g/mol
Drug class
PCSK9 inhibitorrecombinant fusion protein lipid-lowering biologic
Mechanism of action
Binds proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity and prevents PCSK9 binding to hepatic LDL receptors, reducing receptor degradation and increasing LDL-receptor availability to clear LDL cholesterol from the blood.
Indications / reported uses
  • Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, under the US FDA LEROCHOL indication (approved 12 December 2025)

Sources: US FDA prescribing information — LEROCHOL, revised August 2026 · NLM DailyMed — LEROCHOL (lerodalcibep-liga) · FDA Drug Trials Snapshot — LEROCHOL · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

PCSK9 inhibitor; recombinant fusion protein lipid-lowering biologic

Mechanism of action

Binds proprotein convertase subtilisin/kexin type 9 (PCSK9) with high affinity and prevents PCSK9 binding to hepatic LDL receptors, reducing receptor degradation and increasing LDL-receptor availability to clear LDL cholesterol from the blood.

General use cases

  • Adjunct to diet and exercise to reduce LDL cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, under the US FDA LEROCHOL indication (approved 12 December 2025)

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Lerodalcibep PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Lerodalcibep Permitted Daily Exposure (PDE) report (the Lerodalcibep PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Lerodalcibep Occupational Exposure Limit (OEL) report (the Lerodalcibep OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.